Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells

Biomedicine and Pharmacotherapy

Volumn 67, Issue 7, 2013, Pages 615-619

  Yu, Dong feng ^a   Wu, Fan rong ^a   Liu, Yi ^a   Liu, Hong ^a   Xia, Quan ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Apoptosis; Bcl 2; Gastric adenocarcinoma cell; Small interfering RNA (siRNA)

Indexed keywords

FLUOROURACIL; LIPOSOME; PROTEIN BCL 2; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; ASSAY; CARCINOMA CELL; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; WESTERN BLOTTING;

5-FLUOROURACIL; APOPTOSIS; BCL-2; GASTRIC ADENOCARCINOMA CELL; SMALL INTERFERING RNA (SIRNA);

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 84884814494     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.03.007     Document Type: Article

References (18)

1. Parkin D.M. International variation. Oncogene 2004, 23:6329-6340.
2. Jemal A., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Morse M.A., Stoner G.D. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993, 14:1737-1746.
4. Macdonald J.S. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004, 54(Suppl. 1):S4-S11.
5. Zhang D., Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007, 7:1369-1378.
6. Debatin K.M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004, 53:153-159.
7. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol 2012, 13:1426-1438.
8. Krajewska M., et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996, 149:1449-1457.
9. Tomomi K., Donald D.N. Bcl-2 family proteins and the role of mitochondria in apoptosis. Curr Opin Cel Bio 2003, 15:691-699.
10. Mounier N., et al. Rituximab plus CHOP (RCHOP) overcomes Bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003, 101:4279-4284.
11. Juin P., et al. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta 2004, 1644:251-260.
12. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
13. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007, 8:23-36.
14. Reynolds A., et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004, 22:326-330.
15. Zhang C.X., Huang K.X. Mechanism of apoptosis induced by a polysaccharide, from the loach Misgurnus anguillicaudatus (MAP) in human hepatocellular carcinoma cells. Toxicol Appl Pharmacol 2006, 210:236-245.
16. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
17. Shah M.A. Recent developments in the treatment of gastric carcinoma. Curr Oncol Rep 2002, 4:193-201.
18. McManus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002, 3:737-747.